Phase I study of sapacitabine and seliciclib in patients with advanced solid tumours

Bookmark and Share
Published: 6 Jun 2016
Views: 1200
Dr Sara Tolaney - Dana Farber Cancer Institute, Boston, USA

Dr Tolaney speaks with ecancertv at ASCO 2016, presenting her research on combined sapacitibine/seciciclib therapy in BRCA tumours.

Though termed a combination therapy, the schedule by which the two drugs are administered has significant impact on their overall efficacy.

She explains the mechanisms through which DNA damage is introduced to tumour cells, and their cell cycle progression slowed, resulting in apoptosis.

These results indicate the potential role of BRCA as a biomarker for therapy selection, and Dr Tolaney identifies further trials of 'sap-sec' in different patient cohorts.